RASAL2 confers collateral MEK/EGFR dependency in chemoresistant triple-negative breast cancer. Koh SB, Ross K, Isakoff SJ, Melkonjan N, et al. Clin Cancer Res 2021 Jun 24. pii: 1078-0432.CCR-21-0714.

Read + Share

Amedeo Smart

Independent Medical Education

Koh SB, Ross K, Isakoff SJ, Melkonjan N, et al. RASAL2 confers collateral MEK/EGFR dependency in chemoresistant triple-negative breast cancer. Clin Cancer Res 2021 Jun 24. pii: 1078-0432.CCR-21-0714.
PMID: 34168046